Oxidative Stress and Asprosin Levels in Type 2 Diabetic Patients with Good and Poor Glycemic Control
HbA1c is the most widely used test as an indicator of glucoregulation in patients with type 2 diabetes mellitus (T2DM). Asprosin and oxidative stress levels can be reduced with good glycemic control (GC) and thus prevented or delayed micro/macro complications in patients with T2DM. The relationship...
Saved in:
Published in | Biomolecules (Basel, Switzerland) Vol. 14; no. 9; p. 1123 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
MDPI AG
05.09.2024
MDPI |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | HbA1c is the most widely used test as an indicator of glucoregulation in patients with type 2 diabetes mellitus (T2DM). Asprosin and oxidative stress levels can be reduced with good glycemic control (GC) and thus prevented or delayed micro/macro complications in patients with T2DM. The relationship between asprosin, which is thought to affect GC, and oxidative stress parameters such as lipid hydroperoxides (LOOHs), glutathione (GSH), malondialdehyde (MDA), superoxide dismutase (Cu,Zn-SOD), and total antioxidant capacity (TAC) was evaluated in T2DM patients.
The study was conducted prospectively in 75 healthy people admitted to the hospital for a general health check-up and 150 T2DM patients treated in the diabetes outpatient clinic. The patient's glycemic status measurements were categorized as good glycemic control group (GGC) is defined as HbA1c < 7 and poor glycemic control (PGC) group is defined as HbA1c ≥ 7.
The study found a consistent increase in LOOH and MDA levels across the control, GGC, and PGC groups, while GSH, Cu/Zn-SOD, and TAC levels decreased in these respective groups. Additionally, asprosin levels showed a gradual rise in all groups. Positive correlations were observed between asprosin levels and various metabolic and oxidative stress markers, including BMI, WC, FBG, insulin, homeostasis model assessment for insulin resistance (HOMA-IR), DM duration, LOOH, and MDA, while negative correlations were noted with GSH, Cu/Zn-SOD, and TAC specifically in the PGC group. Furthermore, multivariate regression analysis identified HOMA-IR as the primary influencing factor on asprosin levels in PGC patients.
Current glycemic dysregulation may lead to increased circulating asprosin and oxidative stress, which cause complications. Since asprosin levels may be an important hormonal factor in determining GC in T2DM, the use of this hormone may be recommended in the future to accelerate therapeutic approaches in T2DM. Early diagnosis and appropriate treatment may delay the development and progression of diabetic complications. |
---|---|
AbstractList | Objectives: HbA1c is the most widely used test as an indicator of glucoregulation in patients with type 2 diabetes mellitus (T2DM). Asprosin and oxidative stress levels can be reduced with good glycemic control (GC) and thus prevented or delayed micro/macro complications in patients with T2DM. The relationship between asprosin, which is thought to affect GC, and oxidative stress parameters such as lipid hydroperoxides (LOOHs), glutathione (GSH), malondialdehyde (MDA), superoxide dismutase (Cu,Zn-SOD), and total antioxidant capacity (TAC) was evaluated in T2DM patients. Materials and Methods: The study was conducted prospectively in 75 healthy people admitted to the hospital for a general health check-up and 150 T2DM patients treated in the diabetes outpatient clinic. The patient's glycemic status measurements were categorized as good glycemic control group (GGC) is defined as HbA1c < 7 and poor glycemic control (PGC) group is defined as HbA1c ≥ 7. Results: The study found a consistent increase in LOOH and MDA levels across the control, GGC, and PGC groups, while GSH, Cu/Zn-SOD, and TAC levels decreased in these respective groups. Additionally, asprosin levels showed a gradual rise in all groups. Positive correlations were observed between asprosin levels and various metabolic and oxidative stress markers, including BMI, WC, FBG, insulin, homeostasis model assessment for insulin resistance (HOMA-IR), DM duration, LOOH, and MDA, while negative correlations were noted with GSH, Cu/Zn-SOD, and TAC specifically in the PGC group. Furthermore, multivariate regression analysis identified HOMA-IR as the primary influencing factor on asprosin levels in PGC patients. Conclusions: Current glycemic dysregulation may lead to increased circulating asprosin and oxidative stress, which cause complications. Since asprosin levels may be an important hormonal factor in determining GC in T2DM, the use of this hormone may be recommended in the future to accelerate therapeutic approaches in T2DM. Early diagnosis and appropriate treatment may delay the development and progression of diabetic complications.Objectives: HbA1c is the most widely used test as an indicator of glucoregulation in patients with type 2 diabetes mellitus (T2DM). Asprosin and oxidative stress levels can be reduced with good glycemic control (GC) and thus prevented or delayed micro/macro complications in patients with T2DM. The relationship between asprosin, which is thought to affect GC, and oxidative stress parameters such as lipid hydroperoxides (LOOHs), glutathione (GSH), malondialdehyde (MDA), superoxide dismutase (Cu,Zn-SOD), and total antioxidant capacity (TAC) was evaluated in T2DM patients. Materials and Methods: The study was conducted prospectively in 75 healthy people admitted to the hospital for a general health check-up and 150 T2DM patients treated in the diabetes outpatient clinic. The patient's glycemic status measurements were categorized as good glycemic control group (GGC) is defined as HbA1c < 7 and poor glycemic control (PGC) group is defined as HbA1c ≥ 7. Results: The study found a consistent increase in LOOH and MDA levels across the control, GGC, and PGC groups, while GSH, Cu/Zn-SOD, and TAC levels decreased in these respective groups. Additionally, asprosin levels showed a gradual rise in all groups. Positive correlations were observed between asprosin levels and various metabolic and oxidative stress markers, including BMI, WC, FBG, insulin, homeostasis model assessment for insulin resistance (HOMA-IR), DM duration, LOOH, and MDA, while negative correlations were noted with GSH, Cu/Zn-SOD, and TAC specifically in the PGC group. Furthermore, multivariate regression analysis identified HOMA-IR as the primary influencing factor on asprosin levels in PGC patients. Conclusions: Current glycemic dysregulation may lead to increased circulating asprosin and oxidative stress, which cause complications. Since asprosin levels may be an important hormonal factor in determining GC in T2DM, the use of this hormone may be recommended in the future to accelerate therapeutic approaches in T2DM. Early diagnosis and appropriate treatment may delay the development and progression of diabetic complications. Objectives: HbA1c is the most widely used test as an indicator of glucoregulation in patients with type 2 diabetes mellitus (T2DM). Asprosin and oxidative stress levels can be reduced with good glycemic control (GC) and thus prevented or delayed micro/macro complications in patients with T2DM. The relationship between asprosin, which is thought to affect GC, and oxidative stress parameters such as lipid hydroperoxides (LOOHs), glutathione (GSH), malondialdehyde (MDA), superoxide dismutase (Cu,Zn-SOD), and total antioxidant capacity (TAC) was evaluated in T2DM patients. Materials and Methods: The study was conducted prospectively in 75 healthy people admitted to the hospital for a general health check-up and 150 T2DM patients treated in the diabetes outpatient clinic. The patient’s glycemic status measurements were categorized as good glycemic control group (GGC) is defined as HbA1c < 7 and poor glycemic control (PGC) group is defined as HbA1c ≥ 7. Results: The study found a consistent increase in LOOH and MDA levels across the control, GGC, and PGC groups, while GSH, Cu/Zn-SOD, and TAC levels decreased in these respective groups. Additionally, asprosin levels showed a gradual rise in all groups. Positive correlations were observed between asprosin levels and various metabolic and oxidative stress markers, including BMI, WC, FBG, insulin, homeostasis model assessment for insulin resistance (HOMA-IR), DM duration, LOOH, and MDA, while negative correlations were noted with GSH, Cu/Zn-SOD, and TAC specifically in the PGC group. Furthermore, multivariate regression analysis identified HOMA-IR as the primary influencing factor on asprosin levels in PGC patients. Conclusions: Current glycemic dysregulation may lead to increased circulating asprosin and oxidative stress, which cause complications. Since asprosin levels may be an important hormonal factor in determining GC in T2DM, the use of this hormone may be recommended in the future to accelerate therapeutic approaches in T2DM. Early diagnosis and appropriate treatment may delay the development and progression of diabetic complications. HbA1c is the most widely used test as an indicator of glucoregulation in patients with type 2 diabetes mellitus (T2DM). Asprosin and oxidative stress levels can be reduced with good glycemic control (GC) and thus prevented or delayed micro/macro complications in patients with T2DM. The relationship between asprosin, which is thought to affect GC, and oxidative stress parameters such as lipid hydroperoxides (LOOHs), glutathione (GSH), malondialdehyde (MDA), superoxide dismutase (Cu,Zn-SOD), and total antioxidant capacity (TAC) was evaluated in T2DM patients. The study was conducted prospectively in 75 healthy people admitted to the hospital for a general health check-up and 150 T2DM patients treated in the diabetes outpatient clinic. The patient's glycemic status measurements were categorized as good glycemic control group (GGC) is defined as HbA1c < 7 and poor glycemic control (PGC) group is defined as HbA1c ≥ 7. The study found a consistent increase in LOOH and MDA levels across the control, GGC, and PGC groups, while GSH, Cu/Zn-SOD, and TAC levels decreased in these respective groups. Additionally, asprosin levels showed a gradual rise in all groups. Positive correlations were observed between asprosin levels and various metabolic and oxidative stress markers, including BMI, WC, FBG, insulin, homeostasis model assessment for insulin resistance (HOMA-IR), DM duration, LOOH, and MDA, while negative correlations were noted with GSH, Cu/Zn-SOD, and TAC specifically in the PGC group. Furthermore, multivariate regression analysis identified HOMA-IR as the primary influencing factor on asprosin levels in PGC patients. Current glycemic dysregulation may lead to increased circulating asprosin and oxidative stress, which cause complications. Since asprosin levels may be an important hormonal factor in determining GC in T2DM, the use of this hormone may be recommended in the future to accelerate therapeutic approaches in T2DM. Early diagnosis and appropriate treatment may delay the development and progression of diabetic complications. Objectives: HbA1c is the most widely used test as an indicator of glucoregulation in patients with type 2 diabetes mellitus (T2DM). Asprosin and oxidative stress levels can be reduced with good glycemic control (GC) and thus prevented or delayed micro/macro complications in patients with T2DM. The relationship between asprosin, which is thought to affect GC, and oxidative stress parameters such as lipid hydroperoxides (LOOHs), glutathione (GSH), malondialdehyde (MDA), superoxide dismutase (Cu,Zn-SOD), and total antioxidant capacity (TAC) was evaluated in T2DM patients. Materials and Methods: The study was conducted prospectively in 75 healthy people admitted to the hospital for a general health check-up and 150 T2DM patients treated in the diabetes outpatient clinic. The patient’s glycemic status measurements were categorized as good glycemic control group (GGC) is defined as HbA1c < 7 and poor glycemic control (PGC) group is defined as HbA1c ≥ 7. Results: The study found a consistent increase in LOOH and MDA levels across the control, GGC, and PGC groups, while GSH, Cu/Zn-SOD, and TAC levels decreased in these respective groups. Additionally, asprosin levels showed a gradual rise in all groups. Positive correlations were observed between asprosin levels and various metabolic and oxidative stress markers, including BMI, WC, FBG, insulin, homeostasis model assessment for insulin resistance (HOMA-IR), DM duration, LOOH, and MDA, while negative correlations were noted with GSH, Cu/Zn-SOD, and TAC specifically in the PGC group. Furthermore, multivariate regression analysis identified HOMA-IR as the primary influencing factor on asprosin levels in PGC patients. Conclusions: Current glycemic dysregulation may lead to increased circulating asprosin and oxidative stress, which cause complications. Since asprosin levels may be an important hormonal factor in determining GC in T2DM, the use of this hormone may be recommended in the future to accelerate therapeutic approaches in T2DM. Early diagnosis and appropriate treatment may delay the development and progression of diabetic complications. |
Audience | Academic |
Author | Uzun, Hafize Senyigit, Abdulhalim Durmus, Sinem Gelisgen, Remise |
AuthorAffiliation | 2 Department of Medical Biochemistry, Faculty of Medicine, Izmir Katip Celebi University, Izmir 35620, Türkiye; durmus.sinem@gmail.com 3 Department of Biochemistry, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34320,Türkiye; remise.gelisgen@iuc.edu.tr 1 Department of Internal Medicine, Faculty of Medicine, Istanbul Atlas University, Istanbul 34408, Türkiye; abdulhalim.senyigit@atlas.edu.tr 4 Department of Biochemistry, Faculty of Medicine, Istanbul Atlas University, Istanbul 34408, Türkiye |
AuthorAffiliation_xml | – name: 3 Department of Biochemistry, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34320,Türkiye; remise.gelisgen@iuc.edu.tr – name: 1 Department of Internal Medicine, Faculty of Medicine, Istanbul Atlas University, Istanbul 34408, Türkiye; abdulhalim.senyigit@atlas.edu.tr – name: 4 Department of Biochemistry, Faculty of Medicine, Istanbul Atlas University, Istanbul 34408, Türkiye – name: 2 Department of Medical Biochemistry, Faculty of Medicine, Izmir Katip Celebi University, Izmir 35620, Türkiye; durmus.sinem@gmail.com |
Author_xml | – sequence: 1 givenname: Abdulhalim surname: Senyigit fullname: Senyigit, Abdulhalim organization: Department of Internal Medicine, Faculty of Medicine, Istanbul Atlas University, Istanbul 34408, Türkiye – sequence: 2 givenname: Sinem orcidid: 0000-0002-9272-9098 surname: Durmus fullname: Durmus, Sinem organization: Department of Medical Biochemistry, Faculty of Medicine, Izmir Katip Celebi University, Izmir 35620, Türkiye – sequence: 3 givenname: Remise surname: Gelisgen fullname: Gelisgen, Remise organization: Department of Biochemistry, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34320,Türkiye – sequence: 4 givenname: Hafize orcidid: 0000-0002-1347-8498 surname: Uzun fullname: Uzun, Hafize organization: Department of Biochemistry, Faculty of Medicine, Istanbul Atlas University, Istanbul 34408, Türkiye |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39334889$$D View this record in MEDLINE/PubMed |
BookMark | eNptkk1vEzEQhleoiJbSG2dkiUsPpPgzuz6hKNBQKVIrUSRulteeTR1t1sHeBPLvO0lKSRC2JVvjdx7PeOZ1cdLFDoriLaNXQmj6sQ5xwSTVjHHxojjjnFUDXoofJwfn0-Ii5znFUeHi4lVxKrQQsqr0WeFvfwdv-7AG8q1PkDOxnSejvEwxh45MYQ1tJni63yyBcPI52Br64MgdOkHXZ_Ir9A9kEqPfed7FmMik3ThYoGgcuz7F9k3xsrFthoun_bz4fv3lfvx1ML2d3IxH04GTQvSDuhSSQ2WVa1ytatCeSy4bVlElLNXVUFutJBXWOeps08ihKxWTlnlJh8C9OC9u9lwf7dwsU1jYtDHRBrMzxDQzNmHwLZiaUXAIU8qVkvtS60px8NIOlWOiVsj6tGctV_UCvMNck22PoMc3XXgws7g2jElBhxVFwuUTIcWfK8i9WYTsoG1tB3GVjWCMaqwJ1yh9_490Hlepw7_aqUTJMci_qpnFDELXRHzYbaFmVCFLaVlun736jwqn35YE26cJaD9y-LB3cFjznKB5TpJRs-0yc9hlKH93-DHP4j89JR4BQfTMtg |
Cites_doi | 10.1080/09513590.2018.1512967 10.1152/physrev.00018.2001 10.1016/S0076-6879(78)52032-6 10.2337/dc20-S002 10.3390/ijms14023265 10.2174/1573399816666200716201550 10.1080/0886022X.2023.2220425 10.1093/clinchem/34.3.497 10.1007/s11033-021-06551-2 10.2337/dc09-S310 10.1016/0003-2697(92)90122-N 10.1155/2018/9471583 10.1186/s13104-019-4248-6 10.1007/BF02913083 10.1155/2021/6622129 10.3390/cimb45080420 10.1155/2018/7375294 10.2337/dc18-Sint01 10.4137/BMI.S38440 10.1186/1475-2840-4-5 10.1006/abio.1996.0292 10.4158/EP15672.GLSUPPL 10.1016/j.biocel.2006.07.001 10.1186/s13098-020-00564-w 10.1111/dom.13891 10.3389/fendo.2020.00064 10.1016/j.cca.2017.10.034 10.2337/dc18-S002 10.1038/nm.4432 10.12816/0003082 10.1159/000503808 10.1016/j.cell.2016.02.063 10.1111/jocn.14779 10.1007/s10517-021-05191-7 10.7554/eLife.63784 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2024 MDPI AG 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2024 by the authors. 2024 |
Copyright_xml | – notice: COPYRIGHT 2024 MDPI AG – notice: 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2024 by the authors. 2024 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7T5 7TM 7TO 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.3390/biom14091123 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Biological Science Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Central Essentials Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology |
EISSN | 2218-273X |
ExternalDocumentID | oai_doaj_org_article_b10ec54055c742d799852ed4a65c13b5 A810959470 10_3390_biom14091123 39334889 |
Genre | Journal Article |
GeographicLocations | Istanbul Turkey Turkey United States--US Germany |
GeographicLocations_xml | – name: Germany – name: United States--US – name: Istanbul Turkey – name: Turkey |
GroupedDBID | 3V. 53G 5VS 7X7 88E 8FE 8FH 8FI 8FJ AADQD AAFWJ ABDBF ABUWG ADBBV AFKRA AFPKN AFZYC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CCPQU CGR CUY CVF EBD ECM EIF ESX FYUFA GROUPED_DOAJ HCIFZ HMCUK HYE IAO ITC KQ8 LK8 M1P M7P MODMG M~E NPM OK1 PGMZT PIMPY PQQKQ PROAC PSQYO RIG RPM UKHRP AAYXX CITATION 7T5 7TM 7TO 7XB 8FK AZQEC DWQXO GNUQQ H94 K9. M48 PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c433t-b7342e8a5cfcb5be9d2424f18053a09869a95403acc0caff46c7514a1d406e2d3 |
IEDL.DBID | RPM |
ISSN | 2218-273X |
IngestDate | Tue Oct 22 15:09:52 EDT 2024 Mon Sep 30 11:48:15 EDT 2024 Sat Oct 26 02:12:15 EDT 2024 Thu Oct 10 21:11:05 EDT 2024 Thu Oct 10 02:26:40 EDT 2024 Tue Oct 08 04:17:17 EDT 2024 Wed Sep 11 14:10:30 EDT 2024 Sat Nov 02 12:02:25 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Keywords | T2DM glycemic control asprosin total antioxidant capacity glutathione superoxide dismutase malondialdehyde lipid hydroperoxides |
Language | English |
License | Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c433t-b7342e8a5cfcb5be9d2424f18053a09869a95403acc0caff46c7514a1d406e2d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-9272-9098 0000-0002-1347-8498 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11430680/ |
PMID | 39334889 |
PQID | 3110372742 |
PQPubID | 2032425 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_b10ec54055c742d799852ed4a65c13b5 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11430680 proquest_miscellaneous_3110908029 proquest_journals_3110372742 gale_infotracmisc_A810959470 gale_infotracacademiconefile_A810959470 crossref_primary_10_3390_biom14091123 pubmed_primary_39334889 |
PublicationCentury | 2000 |
PublicationDate | 20240905 |
PublicationDateYYYYMMDD | 2024-09-05 |
PublicationDate_xml | – month: 9 year: 2024 text: 20240905 day: 5 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland – name: Basel |
PublicationTitle | Biomolecules (Basel, Switzerland) |
PublicationTitleAlternate | Biomolecules |
PublicationYear | 2024 |
Publisher | MDPI AG MDPI |
Publisher_xml | – name: MDPI AG – name: MDPI |
References | Li (ref_37) 2018; 2018 Romere (ref_9) 2016; 165 Sherwani (ref_2) 2016; 11 Monnier (ref_4) 2009; 32 Goodarzi (ref_24) 2021; 48 Duerrschmid (ref_8) 2017; 23 Handelsman (ref_5) 2015; 21 Johansen (ref_12) 2005; 4 Mishra (ref_39) 2021; 10 Beutler (ref_18) 1963; 61 Jiang (ref_16) 1992; 202 Wang (ref_22) 2019; 75 ref_19 Sun (ref_20) 1988; 34 Caturano (ref_35) 2023; 45 Benzie (ref_21) 1996; 239 ref_15 Zhou (ref_26) 2023; 45 Zhang (ref_28) 2019; 489 Wang (ref_25) 2018; 2018 Verma (ref_31) 2006; 21 (ref_10) 2002; 82 Matough (ref_13) 2012; 12 Naiemian (ref_23) 2020; 12 Ghouse (ref_32) 2020; 22 (ref_3) 2010; 135 Milo (ref_30) 2019; 28 Ugur (ref_27) 2022; 26 ref_1 Buege (ref_17) 1978; 52 Alan (ref_36) 2019; 35 Rabelo (ref_14) 2013; 14 Valente (ref_33) 2021; 17 Darenskaya (ref_34) 2021; 171 Valko (ref_11) 2007; 39 ref_29 Hong (ref_38) 2021; 2021 ref_7 ref_6 |
References_xml | – volume: 35 start-page: 220 year: 2019 ident: ref_36 article-title: Asprosin: A novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome publication-title: Gynecol. Endocrinol. doi: 10.1080/09513590.2018.1512967 contributor: fullname: Alan – volume: 82 start-page: 47 year: 2002 ident: ref_10 article-title: Free radicals in the physiological control of cell function publication-title: Physiol. Rev. doi: 10.1152/physrev.00018.2001 – volume: 52 start-page: 302 year: 1978 ident: ref_17 article-title: Microsomal lipid peroxidation publication-title: Methods Enzymol. doi: 10.1016/S0076-6879(78)52032-6 contributor: fullname: Buege – ident: ref_1 doi: 10.2337/dc20-S002 – volume: 14 start-page: 3265 year: 2013 ident: ref_14 article-title: Oxidative stress as an underlying contributor in the development of chronic complications in diabetes mellitus publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms14023265 contributor: fullname: Rabelo – volume: 135 start-page: 15 year: 2010 ident: ref_3 article-title: Assessment of glycemic control: New insights into the evaluation of the diabetic patient publication-title: Med. Clin. – volume: 17 start-page: e071620183816 year: 2021 ident: ref_33 article-title: Glycemic Variability, Oxidative Stress, and Impact on Complications Related to Type 2 Diabetes Mellitus publication-title: Curr. Diabetes Rev. doi: 10.2174/1573399816666200716201550 contributor: fullname: Valente – volume: 45 start-page: 2220425 year: 2023 ident: ref_26 article-title: Asprosin is positively associated with metabolic syndrome in hemodialysis patients: A cross-sectional study publication-title: Ren. Fail. doi: 10.1080/0886022X.2023.2220425 contributor: fullname: Zhou – volume: 34 start-page: 497 year: 1988 ident: ref_20 article-title: A simple method for clinical assay of superoxide dismutase publication-title: Clin. Chem. doi: 10.1093/clinchem/34.3.497 contributor: fullname: Sun – volume: 48 start-page: 5443 year: 2021 ident: ref_24 article-title: Circulating levels of asprosin and its association with insulin resistance and renal function in patients with type 2 diabetes mellitus and diabetic nephropathy publication-title: Mol. Biol. Rep. doi: 10.1007/s11033-021-06551-2 contributor: fullname: Goodarzi – volume: 32 start-page: S199 year: 2009 ident: ref_4 article-title: Target for glycemic control: Concentrating on glucose publication-title: Diabetes Care doi: 10.2337/dc09-S310 contributor: fullname: Monnier – volume: 202 start-page: 384 year: 1992 ident: ref_16 article-title: Ferrous ion oxidation in the presence of xylenol orange for detection of lipid hydroperoxide in low density lipoprotein publication-title: Anal. Biochem. doi: 10.1016/0003-2697(92)90122-N contributor: fullname: Jiang – volume: 2018 start-page: 9471583 year: 2018 ident: ref_25 article-title: Plasma Asprosin Concentrations Are Increased in Individuals with Glucose Dysregulation and Correlated with Insulin Resistance and First-Phase Insulin Secretion publication-title: Mediat. Inflamm. doi: 10.1155/2018/9471583 contributor: fullname: Wang – ident: ref_29 doi: 10.1186/s13104-019-4248-6 – volume: 21 start-page: 142 year: 2006 ident: ref_31 article-title: Effect of increasing duration of diabetes mellitus type 2 on glycated hemoglobin and insulin sensitivity publication-title: Indian. J. Clin. Biochem. doi: 10.1007/BF02913083 contributor: fullname: Verma – volume: 2021 start-page: 6622129 year: 2021 ident: ref_38 article-title: High Serum Asprosin Levels Are Associated with Presence of Metabolic Syndrome publication-title: Int. J. Endocrinol. doi: 10.1155/2021/6622129 contributor: fullname: Hong – volume: 61 start-page: 882 year: 1963 ident: ref_18 article-title: Improved method for the determination of blood glutathione publication-title: J. Lab. Clin. Med. contributor: fullname: Beutler – volume: 45 start-page: 6651 year: 2023 ident: ref_35 article-title: Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications publication-title: Curr. Issues Mol. Biol. doi: 10.3390/cimb45080420 contributor: fullname: Caturano – volume: 2018 start-page: 7375294 year: 2018 ident: ref_37 article-title: Plasma Asprosin Levels Are Associated with Glucose Metabolism, Lipid, and Sex Hormone Profiles in Females with Metabolic-Related Diseases publication-title: Mediat. Inflamm. doi: 10.1155/2018/7375294 contributor: fullname: Li – ident: ref_6 doi: 10.2337/dc18-Sint01 – volume: 11 start-page: 95 year: 2016 ident: ref_2 article-title: Signifcance of HbA1c test in diagnosis and prognosis of diabetic patients publication-title: Biomark. Insights doi: 10.4137/BMI.S38440 contributor: fullname: Sherwani – volume: 4 start-page: 5 year: 2005 ident: ref_12 article-title: Oxidative stress and the use of antioxidants in diabetes: Linking basic science to clinical practice publication-title: Cardiovasc. Diabetol. doi: 10.1186/1475-2840-4-5 contributor: fullname: Johansen – volume: 239 start-page: 70 year: 1996 ident: ref_21 article-title: The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: The FRAP assay publication-title: Anal. Biochem. doi: 10.1006/abio.1996.0292 contributor: fullname: Benzie – volume: 21 start-page: 1 year: 2015 ident: ref_5 article-title: American association of clinical endocrinologists and American college of endocrinology—Clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015 publication-title: Endocr. Pract. doi: 10.4158/EP15672.GLSUPPL contributor: fullname: Handelsman – volume: 39 start-page: 44 year: 2007 ident: ref_11 article-title: Free radicals and antioxidants in normal physiological functions and human disease publication-title: Int. J. Biochem. Cell Biol. doi: 10.1016/j.biocel.2006.07.001 contributor: fullname: Valko – volume: 12 start-page: 65 year: 2020 ident: ref_23 article-title: Serum concentration of asprosin in new-onset type 2 diabetes publication-title: Diabetol. Metab. Syndr. doi: 10.1186/s13098-020-00564-w contributor: fullname: Naiemian – volume: 26 start-page: 2124 year: 2022 ident: ref_27 article-title: Asprosin, visfatin and subfatin as new biomarkers of obesity and metabolic syndrome publication-title: Eur. Rev. Med. Pharmacol. Sci. contributor: fullname: Ugur – volume: 22 start-page: 231 year: 2020 ident: ref_32 article-title: Effect of diabetes duration on the relationship between glycaemic control and risk of death in older adults with type 2 diabetes publication-title: Diabetes Obes. Metab. doi: 10.1111/dom.13891 contributor: fullname: Ghouse – ident: ref_7 doi: 10.3389/fendo.2020.00064 – volume: 489 start-page: 183 year: 2019 ident: ref_28 article-title: Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride publication-title: Clin. Chim. Acta doi: 10.1016/j.cca.2017.10.034 contributor: fullname: Zhang – ident: ref_15 doi: 10.2337/dc18-S002 – volume: 23 start-page: 1444 year: 2017 ident: ref_8 article-title: Asprosin is a centrally acting orexigenic hormone publication-title: Nat. Med. doi: 10.1038/nm.4432 contributor: fullname: Duerrschmid – ident: ref_19 – volume: 12 start-page: 5 year: 2012 ident: ref_13 article-title: The role of oxidative stress and antioxidants in diabetic complications publication-title: Sultan Qaboos Univ. Med. J. doi: 10.12816/0003082 contributor: fullname: Matough – volume: 75 start-page: 205 year: 2019 ident: ref_22 article-title: Serum Asprosin Concentrations Are Increased and Associated with Insulin Resistance in Children with Obesity publication-title: Ann. Nutr. Metab. doi: 10.1159/000503808 contributor: fullname: Wang – volume: 165 start-page: 566 year: 2016 ident: ref_9 article-title: Asprosin, a Fasting-Induced Glucogenic Protein Hormone publication-title: Cell doi: 10.1016/j.cell.2016.02.063 contributor: fullname: Romere – volume: 28 start-page: 1737 year: 2019 ident: ref_30 article-title: Predictors of glycemic management among patients with type 2 diabetes publication-title: J. Clin. Nurs. doi: 10.1111/jocn.14779 contributor: fullname: Milo – volume: 171 start-page: 179 year: 2021 ident: ref_34 article-title: Oxidative Stress: Pathogenetic Role in Diabetes Mellitus and Its Complications and Therapeutic Approaches to Correction publication-title: Bull. Exp. Biol. Med. doi: 10.1007/s10517-021-05191-7 contributor: fullname: Darenskaya – volume: 10 start-page: e63784 year: 2021 ident: ref_39 article-title: Asprosin-neutralizing antibodies as a treatment for metabolic syndrome publication-title: eLife doi: 10.7554/eLife.63784 contributor: fullname: Mishra |
SSID | ssj0000800823 |
Score | 2.3474157 |
Snippet | HbA1c is the most widely used test as an indicator of glucoregulation in patients with type 2 diabetes mellitus (T2DM). Asprosin and oxidative stress levels... Objectives: HbA1c is the most widely used test as an indicator of glucoregulation in patients with type 2 diabetes mellitus (T2DM). Asprosin and oxidative... Objectives: HbA1c is the most widely used test as an indicator of glucoregulation in patients with type 2 diabetes mellitus (T2DM). Asprosin and oxidative... |
SourceID | doaj pubmedcentral proquest gale crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 1123 |
SubjectTerms | Adipokines Adult Aged Antilipemic agents Antioxidants Antioxidants - metabolism asprosin Biomarkers - blood Blood diseases Blood Glucose - metabolism Blood sugar Body mass index Creatinine Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - metabolism Diabetes therapy Diabetics Female Fibrillin-1 - blood Fibrillin-1 - metabolism Free radicals Glucose Glutathione Glutathione - blood Glutathione - metabolism Glycated Hemoglobin - analysis Glycated Hemoglobin - metabolism Glycemic Control Hemoglobin Homeostasis Hospitals Humans Insulin Insulin resistance Laboratories lipid hydroperoxides Lipid peroxidation Lipids Male malondialdehyde Malondialdehyde - blood Malondialdehyde - metabolism Medical research Medicine, Experimental Middle Aged Outpatient care facilities Oxidative Stress Patients Prospective Studies Proteins Superoxide dismutase Superoxide Dismutase - blood Superoxide Dismutase - metabolism T2DM Urine Zinc |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQUB6BgozE4xTVsZONfVwq2grxqASVerPssSMWQYKarUT_PTN2ukrEgQu3KHYSZx7xjPPNZ8ZeCu2IGEuUQPyXtWvr0hsvyqarguhk8CHtdfjx0-r0vH5_0VzMtvoiTFimB86CO_SViEBhRYN3k6HF9KCRMdRu1UClfGYvFWaWTH2f4iAtVUa6K8zrD6mancidML5QizkoUfX__UGezUhLtORs-jm-y-5McSNf5_HeY7dif5_tr3vMmX9e89c8ITnTEvk-C59_b0Ii9OZfUikId33g6xEfOm56_oFwQiPHI0pCueQZFbMBfpZJVkdOq7P8ZBhCuvJsGC75yY9rICA9P8rg9gfs_Pjd16PTctpNoYRaqW3pW1XLqF0DHfjGRxOoMqSrNLqhE0avjDMoZ-UABLiuq1fQYjTlqoBzfpRBPWR7_dDHx4xLTzepMPbDbiEYB06DEx0Ge8FDFAV7dSNf-yuTZlhMNkgPdq6Hgr0l4e_6ENV1OoEGYCcDsP8ygIK9IdVZckjUD7iprgCHStRWdq0rWuusWxzWwaInOhIsm2-UbydHHq2qqJCS_mcX7MWuma4kcFofh6vcx1DNsinYo2wru1dShkqdNbbohRUt3nnZ0m--JZpvzFQV7Yzy5H9I6Sm7LTEcS-i45oDtbS-v4jMMp7b-efKcPybeHSc priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLage-EFDcYlYyAjcXmK5thJYz-hbtpFCEYFTNqb5VugEiSj6ST27znHcUsjJN6q2mmdHB_7Oyff-UzIKyYNCmOx3KH-ZWnqMrfKsrxqCs8a7q2PZx1-vJieX5bvr6qrlHDrE61yvSbGhdp3DnPkh6LAijZ8sfju-leOp0bh29V0hMZdssMhUmATsnN0cjH_vMmyIB6SXAyMdwHx_SFWtaPIE-AMMdqLomT_vwvz1s40Zk1ubUOnu-R-wo90Nhj8AbkT2odkb9ZC7Pzzlr6hkdEZU-V7xH_6vfBR2Jt-iSUh1LSeznr4037R0g_IF-opfMJglHI6sGMWjs4HsdWeYpaWnnWdj1fOu25Jz37cOiTU0-OB5P6IXJ6efD0-z9OpCrkrhVjlthYlD9JUrnG2skF5rBBpCgnuaJiSU2UUwDhhnGPONE05dTWgKlN42PsD9-IxmbRdG54Syi3-SAEYELp5r4wz0hnWAOjz1gWWkdfr56uvB_EMDUEH2kFv2yEjR_jwN31Q8jp-0S2_6eRB2hYsOMSXFUwr7muIEysefGmmlSuErTLyFk2n0THBPs6k-gIYKkpc6ZksMOdZ1jCsg1FPcCg3bl4bXyeH7vXf6ZeRl5tmvBJJam3oboY-CmuXVUaeDHNlc0tCYcmzhBY5mkWjex63tIvvUe4bIlaBJ6Ts_39cz8g9DoAr8t-qAzJZLW_CcwBMK_siecUfdxgWkQ priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwEB4ty4ULApZHYEFG4nEKJE7c2AeEyordFeKxElTqzfIrULQk0HSl7b9nxkmrRou4VbWTOp5x_Y3zzTcAzzJpSBgrSx3pX5amKlOrbJaKOvdZzb31sdbhp8-T01n5YS7me7CpNjpMYPfP0I7qSc2W568u_6zf4oJ_QxEnhuyvKVGddJsQOhTX4DovMUYnEt8A9H8OuEjGWm8c9zTKR5n3LPgrNxjtT1HG_-qf9c5uNWZS7mxNx7fg5oAp2bR3gtuwF5o7cDBtMJ7-tWYvWGR5xuPzA_BfLhc-in2zrzFNhJnGs2mHP9otGvaROEQdw08UoDLOesbMwrGzXoC1Y3Ryy07a1scrz9p2yU7O145I9uyoJ77fhdnx-29Hp-lQaSF1OFmr1FZFyYM0wtXOChuUp6yROpe4RE2m5EQZhdCuMM5lztR1OXEVIi2Te8QDgfviHuw3bRMeAOOWbpIjLsRu3ivjjHQmqxEIeutClsDzzfzq372ghsZAhOygd-2QwDua_G0fksGOX7TL73pYVdrmWXCEOQW6GvcVxo6CB1-aiXB5YUUCL8l0mtwH7ePMkHOAQyXZKz2VOZ2DlhUO63DUExeZGzdvjK83PqqLnJIs6V13Ak-3zXQlEdea0F70fRTlM6sE7ve-sn2kQlEatMQWOfKi0TOPW5rFjygBjlFsQVVTHv5_2I_gBkcQFjlx4hD2V8uL8BhB1Mo-ievjL_7VGZ8 priority: 102 providerName: Scholars Portal |
Title | Oxidative Stress and Asprosin Levels in Type 2 Diabetic Patients with Good and Poor Glycemic Control |
URI | https://www.ncbi.nlm.nih.gov/pubmed/39334889 https://www.proquest.com/docview/3110372742 https://www.proquest.com/docview/3110908029 https://pubmed.ncbi.nlm.nih.gov/PMC11430680 https://doaj.org/article/b10ec54055c742d799852ed4a65c13b5 |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB615cIFAeVhWqJF4nFyY3v9PKZRH0KkRECl3Kx9uRg1dhWnUvvvmVnbkS1uXKIouxuvPTPZbzbffAvw0UsFCWN5riL9y1AkoSsz6blR4WuvCLTU9qzDxVV8eR1-XUWrPYj7WhhL2leyPKlu1ydV-dtyK-_WatrzxKbLxRwxPKczI6b7sI8eOsjR_3QYKA14y3LnmNNPqZKdhJ0QW9C5OTyj8lM62H2wFFnF_n9_lwcL05g0OViFzp_Dsw4-slk7zRewZ6qXcDirMHVeP7LPzBI67U75IejvD6W2ut7sp60IYaLSbNbgRZuyYt-ILtQwfEe5KAtYS44pFVu2WqsNo01adlHX2o5c1vWGXdw-KuLTs3nLcX8F1-dnv-aXbneogqtCzreuTHgYmFREqlAykibTVCBS-ClGo_CyNM5EhiiOC6U8JYoijFWCoEr4Gpd-E2j-Gg6qujJvgQWSvsRHCIjdtM6EEqkSXoGYT0tlPAc-9c83v2u1M3LMOcgk-dAkDpzSw9_1IcVr-0G9uck7u-fS94wieBmhVwU6wTQxCowORRwpn8vIgS9kupziEu2jRFdegFMlhat8lvq05RkmOK3jUU-MJzVu7o2fd_Hc5Nynekr6W9uBD7tmGkkctcrU922fjEqXMwfetL6yu6Xe5RxIR140uudxCzq_Vfvunf3d_w89gqcBYjFLjYuO4WC7uTfvEUtt5QQDaJVM4Mnp2dXyx8TuSODrIkwnNqj-AhWgIvE |
link.rule.ids | 230,315,730,783,787,867,888,2109,2228,12068,21400,24330,27936,27937,31731,31732,33756,33757,43322,43817,53804,53806,74079,74636 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgPMALAgYsbICR-HiK5sRxYz-hMrEV6MYkNqlvlr-yVYJkazqJ_ffcOWlphMRbFTup4_PZd5ff_Y6Qt0waJMZiqUP-y8KURWqVZamoMs-q3Fsfax0en4wm58XXmZj1Abe2h1Wu9sS4UfvGYYx8n2eY0YYfFj9eXadYNQq_rvYlNO6Se8jDhRUMylm5jrGgNSRz3uHdOXj3-5jTjhRPYGXwwUkUCfv_3ZY3zqUhZnLjEDp8RB721iMdd-J-TO6E-gnZHtfgOf-6pe9pxHPGQPk28d9_z32k9aY_YkIINbWn4xb-tJ3XdIpooZbCL3RFaU47bMzc0dOOarWlGKOlR03j452nTbOgRz9vHcLp6UEHcX9Kzg8_nx1M0r6mQupghpapLXmRB2mEq5wVNiiP-SFVJkEZDVNypIwCI44b55gzVVWMXAk2lck8nPwh9_wZ2aqbOuwQmlt8SAYWIHTzXhlnpDOsApPPWxdYQt6t5ldfddQZGlwOlIPelENCPuHkr_sg4XW80CwudK8_2mYsOLQuBSyq3JfgJYo8-MKMhMu4FQn5gKLTqJYgH2f67AIYKhJc6bHMMOJZlDCsvUFPUCc3bF4JX_fq3Oq_iy8hb9bNeCdC1OrQ3HR9FGYuq4Q879bK-pW4woRnCS1ysIoG7zxsqeeXkewb_FWO9VFe_H9cr8n9ydnxVE-_nHzbJQ9yML0iEk7ska3l4ia8BNNpaV9F_fgDDuAYHA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgSIiXCRgfgTGMxMdT1MROGvsJdYNuwBiVYFLfLH-FVYJkNJ3E_nvuHLc0QuKtqp3Wyd3Zv7v87o6Ql5nQWBgrSy3Wvyx0VaRGmiwt69xlNXPGhV6Hn8_GJ-fFx3k5j_ynLtIq13ti2KhdazFGPuI5ZrThi8VRHWkRs3fTt5e_UuwghW9aYzuNm-RWBV4Kang1rzbxFkRGgvGe-87B0x9hfjuWewLEwQenUije_-8WvXVGDfmTWwfS9C7ZjUiSTnrR3yM3fHOf7E0a8KJ_XtPXNHA7Q9B8j7gvvxculPimX0NyCNWNo5MO_rRbNPQUmUMdhU_ollJGe57MwtJZX3a1oxivpcdt68KVs7Zd0uMf1xap9fSop7s_IOfT99-OTtLYXyG1Beer1FS8YF7o0tbWlMZLh7kidS7AMHUmxVhqCYCOa2szq-u6GNsK8JXOHaAAzxx_SHaatvGPCWUGfyQHNAjTnJPaamF1VgP8c8b6LCGv1s9XXfZlNBS4HygHtS2HhBziw9_MweLX4Yt2-V1FW1Imz7xFpFmCgjFXgcdYMu8KPS5tzk2ZkDcoOoUmCvKxOmYawFKx2JWaiByjn0UFy9ofzATTssPhtfBVNO1O_VXEhLzYDOOVSFdrfHvVz5GYxSwT8qjXlc0tcYnJzwJGxECLBvc8HGkWF6HwN_iuHHulPPn_up6T22Aa6vTD2aen5A4DFBZIceU-2Vktr_wzQFErcxDM4w9KQRxa |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Oxidative+Stress+and+Asprosin+Levels+in+Type+2+Diabetic+Patients+with+Good+and+Poor+Glycemic+Control&rft.jtitle=Biomolecules+%28Basel%2C+Switzerland%29&rft.au=Senyigit%2C+Abdulhalim&rft.au=Durmus%2C+Sinem&rft.au=Gelisgen%2C+Remise&rft.au=Uzun%2C+Hafize&rft.date=2024-09-05&rft.pub=MDPI+AG&rft.issn=2218-273X&rft.eissn=2218-273X&rft.volume=14&rft.issue=9&rft_id=info:doi/10.3390%2Fbiom14091123&rft.externalDocID=A810959470 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2218-273X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2218-273X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2218-273X&client=summon |